---
title: "Relapsed Disease of mantle cell lymphoma"
slug: "relapsed-disease-of-mantle-cell-lymphoma"
date: "2023-06-18"
enableToc: false
tags:
- building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[mantle cell lymphoma]]

# Relapsed Disease of mantle cell lymphoma

- No generally accepted standard of care; clinical trial enrollment encouraged
The above described initial Rx regimens are typically also active in the relapsed setting if not already used
- Lenalidomide plus rituximab is active in relapsed MCL (Lancet Oncol 2012;13:716)
- Ibrutinib is active in relapsed MCL (NEJM 2013;369:507) & can consider addition of rituximab (Lancet Oncol 2015;17:48)
- Venetoclax is active in relapsed MCL (JCO 2016;70:4320)
- Bortezomib (Â± rituximab) has been approved for salvage Rx based on a single agent ORR of 33% w/ 8% CRs (JCO 2006;24:4867).
- Long-term disease control can be achieved w/ allogeneic SCT. Compared to autologous SCT, allo SCT is a/w increased tox, but improved disease control
